What are the main indications for Datopotamab?

Datopotamab (Datopotamab) is an antibody drug conjugate (ADC) targeting the TROP2 protein, which is effectively combined with an antibody and a topoisomerase I inhibitor. TROP2 is a transmembrane glycoprotein highly expressed on the surface of various solid tumor cells and is closely related to tumor invasiveness, growth rate and metastasis potential. By accurately identifying TROP2 and releasing the active ingredients of chemotherapy, dedabrotomab can achieve "fixed-point blast" killing of tumor cells, which is of epoch-making significance in the field of targeted therapy.

From the global approved indications, dedabrotuzumab has been approved for the treatment of two major types of tumors. The first category is patients with unresectable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Such patients usually have limited response to traditional regimens after experiencing failure of endocrine therapy and chemotherapy. However, dabrotuzumab, by acting on the TROP2 pathway, has shown a high objective response rate (ORR) and the potential to extend progression-free survival (PFS). The second category is patients with locally advanced or metastatic non-small cell lung cancer who have failed treatment with EGFR-targeted drugs and platinum-based chemotherapy. In these cases, dabrotuzumab provides a new treatment option for patients who have been limited by previous therapies.

Research shows that dabrotuzumab has a unique mechanism of action. The antibody part locks on the TROP2 protein on the surface of the tumor, and then releases the connected cytotoxic drug into the tumor cells, triggering DNA fragmentation and apoptosis, thereby killing the tumor. Compared with traditional chemotherapy, the targeted release characteristics of dedabrotomab can reduce damage to normal tissues to a certain extent and have better tolerance.

Currently, China, the United States and the European Union have approved its use for specific tumor types. In the future, as more clinical research advances, its application areas may be expanded to pancreatic cancer, ovarian cancer and other solid tumors with high TROP2 expression.

Reference materials:https://www.google.com.hk/